Novo Nordisk shared the figure from a post-trial analysis of its next-generation experimental drug, with results broken out for women.
Recap by typeshit. Full story at Reuters.
A short item claims a newer group of weight loss drugs beats Ozempic, without naming the drugs or the data behind the claim.
The digital health doctor shares a take on GLP-1 therapy paired with lifestyle change and digital programs, calling the finding unsurprising.
The obesity medicine specialist told a Fall Clinical 2026 panel that sleep apnea, MASH and heart coverage can open GLP-1 access, and that retatrutide could reach market next year.
In a 12-week study of 245 adults, Omada reports its members cut body fat percentage about twice as much as usual care. Results go to WOC 2026 in Boston.
Dr. Zheng says the drugs have been associated with NAION, an eye condition that can cause permanent vision loss, and points to patients with risk factors.
Patients moved off weekly Wegovy injections onto a daily pill, and Men's Journal reports one group's weight outcomes stood out from the rest.
Loading…